CliffBio
small molecule

FLUORESCEIN SODIUM

FLUORESCEIN SODIUM

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameFLUORESCEIN SODIUM
Active ingredientFLUORESCEIN SODIUM
StrengthEQ 500MG BASE/5ML (EQ 100MG BASE/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2023
Marketing statusRX

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FLUORESCEIN SODIUM patent cliff — loss of exclusivity — | CliffBio